Author response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease

We thank Dr. Ashford for his comment on our article INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.(1) Dr. Ashford raises 2 important points: whether a gamma-secretase-modifying (GSM) NSAID such as ibuprofen would likely have given different results and whether the Alzheimer progression score outcome was sufficiently precise to reveal efficacy.